Ignite Creation Date:
2024-05-05 @ 11:20 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00006125
Status:
COMPLETED
Last Update Posted:
2016-07-14
First Post:
2000-08-03
Brief Title:
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkins Lymphoma
Sponsor:
Alliance for Clinical Trials in Oncology
Organization:
Alliance for Clinical Trials in Oncology
Study Overview
Official Title:
A Phase II Study of Sequential Doxorubicin and Topotecan DoxTopo in Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkins Lymphoma NHL
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Combining more than one drug may kill more tumor cells
PURPOSE Phase II trial to study the effectiveness of combining doxorubicin and topotecan in treating patients who have relapsed or refractory intermediate-grade or high-grade non-Hodgkins lymphoma
PURPOSE Phase II trial to study the effectiveness of combining doxorubicin and topotecan in treating patients who have relapsed or refractory intermediate-grade or high-grade non-Hodgkins lymphoma
Detailed Description:
OBJECTIVES
Determine the response rate and time to progression in patients with relapsed or refractory intermediate or high grade non-Hodgkins lymphoma treated with doxorubicin and topotecan
Determine the toxicity of this regimen in these patients
OUTLINE Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5 Treatment repeats every 21 days for up to 6 courses in the absence of disease progression
Patients are followed every 6 months for 2 years and annually for the next 3 years
Determine the response rate and time to progression in patients with relapsed or refractory intermediate or high grade non-Hodgkins lymphoma treated with doxorubicin and topotecan
Determine the toxicity of this regimen in these patients
OUTLINE Patients receive doxorubicin IV over 5-10 minutes on day 1 and topotecan IV over 30 minutes on days 3-5 Treatment repeats every 21 days for up to 6 courses in the absence of disease progression
Patients are followed every 6 months for 2 years and annually for the next 3 years
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| CDR0000068140 | REGISTRY | NCI Physician Data Query | httpsreporternihgovquickSearchU10CA031946 |
| U10CA031946 | NIH | None | None |
| CLB-59906 | None | None | None |